Payment overview · 2025
General Payments
$919.50
46 reported records · 16 companies
Healthcare provider profile · identity verified
Joy Ignacio, NURSE PRACTITIONER
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · REDDING, CA · NPI 1134517667
Verified facts
What the public records show
CMS Open Payments records show Joy Ignacio, NURSE PRACTITIONER received $919.50 in general payments during 2025 across 46 reported records.
Exact Sciences Corporation accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $208.75 | 22.7% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $142.36 | 15.5% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $112.19 | 12.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $73.21 | 8.0% | 4 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $57.96 | 6.3% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $48.59 | 5.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.48 | 4.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.03 | 4.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.32 | 3.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $28.33 | 3.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.90 | 2.8% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $25.28 | 2.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.61 | 2.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $20.28 | 2.2% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $19.75 | 2.1% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $18.46 | 2.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $919.50 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $208.75 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $142.36 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $142.36 | 9 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $112.19 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $73.21 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $73.21 | 4 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $57.96 | 3 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $57.96 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $48.59 | 3 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $44.48 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.03 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.03 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $34.32 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $28.33 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.90 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $25.28 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.61 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $18.46 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ALK-Abello, Inc | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $16.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 470 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 290 | 59 |
| Metformin Hcl | Metformin Hcl | 268 | 73 |
| Lisinopril | Lisinopril | 243 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 192 | 27 |
| Losartan Potassium | Losartan Potassium | 173 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 39 |
| Gabapentin | Gabapentin | 126 | 41 |
| Omeprazole | Omeprazole | 119 | 29 |
| Baclofen | Baclofen | 118 | 22 |
| Glipizide | Glipizide | 114 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 31 |
| Simvastatin | Simvastatin | 99 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 21 |
| Famotidine | Famotidine | 95 | 23 |
| Ibuprofen | Ibuprofen | 92 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 72 | 18 |
| Jardiance | Empagliflozin | 61 | 15 |
| Celecoxib | Celecoxib | 59 | 18 |
| Alendronate Sodium | Alendronate Sodium | 55 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 55 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 13 |
| Tradjenta | Linagliptin | 54 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 22 |
| Carvedilol | Carvedilol | 44 | 13 |
| Naproxen | Naproxen | 43 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 13 |
| Olanzapine | Olanzapine | 41 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | 11 |
| Glimepiride | Glimepiride | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Furosemide | Furosemide | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Piroxicam | Piroxicam | 11 | suppressed |
| Prednisone | Prednisone | 11 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $919.50 · 46 records | Exact Sciences Corporation | ACCRUFER, APTIMA, BEXSERO, Dexcom G6 Transmitter, Doc Band, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), Grastek, Kerendia, MAVYRET, MOUNJARO, NEFFY, NURTEC ODT, OTEZLA, Odactra, REPATHA, Ragwitek, The Cologuard Plus Collection Kit, Veozah, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error